ENX-102

DRUG3 trials

Sponsors

Engrail Therapeutics INC

Conditions

General Anxiety DisorderGeneralized Anxiety DisorderSocial Anxiety Disorder (SAD)

Phase 2

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

CompletedNCT05749055

Engrail Therapeutics INCGeneralized Anxiety Disorder

Start: 2023-07-03End: 2025-09-18Updated: 2025-09-25

A Dose-Response Safety Study of ENX-102 in Patients With GAD

CompletedNCT06653296

Engrail Therapeutics INCGeneral Anxiety Disorder

Start: 2024-12-09End: 2025-06-23Updated: 2025-09-17

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

CompletedNCT07193563

Engrail Therapeutics INCSocial Anxiety Disorder (SAD)

Start: 2025-09-05End: 2026-03-19Updated: 2026-04-08